ライフサイエンスコーパス: hypertonic saline

1 , dextran, gelatin, hydroxyethyl starch, and hypertonic saline).

2 nse after an intraperitoneal injection of 1M hypertonic saline.

3 s that may be up-regulated with edema and/or hypertonic saline.

4 IOP produced by episcleral vein injection of hypertonic saline.

5 ients treated with continuous IV infusion 3% hypertonic saline.

6 urface, which was significantly augmented by hypertonic saline.

7 intracranial disease should be treated with hypertonic saline.

8 eater than in wild-type mice pretreated with hypertonic saline.

9 This response was completely abrogated by hypertonic saline.

10 nt until recently were water restriction and hypertonic saline.

11 ot small bowel organ water was diminished by hypertonic saline.

12 exia is stimulated by chronic consumption of hypertonic saline.

13 tation (equal salt), and MV-HTN with 4 mL/kg hypertonic saline.

14 ithelial Na channels, and resuscitation with hypertonic saline.

15 S) and resuscitated with Ringer's lactate or hypertonic saline.

16 , 4 [3-6] to 7 [6-9]; p = 0.008) after 23.4% hypertonic saline.

17 was seen with and without administration of hypertonic saline.

18 ay rhDNase (2.5 mg), and twice-daily 5 mL 7% hypertonic saline.

19 of 0.9% saline or various concentrations of hypertonic saline.

20 lene glycol and at least one of the doses of hypertonic saline.

21 an albumin, 3.5% hypertonic saline, and 7.5% hypertonic saline.

22 ombination of hyperventilation, mannitol and hypertonic saline.

23 washed with excess chondroitin 6-sulphate or hypertonic saline.

24 ently with nebulized racemic epinephrine and hypertonic saline.

25 CH selected the nebulization technique using hypertonic saline.

26 Continuous IV infusion 3% hypertonic saline.

27 dverse effects theoretically associated with hypertonic saline.

28 es adopted the approach of giving a bolus of hypertonic saline.

29 uced in rats by episcleral vein injection of hypertonic saline.

30 with continuous intravenous infusion of 7.5% hypertonic saline (0.5 mL/hr; acetate/chloride, 50:50) a

31 us intravenous infusion of 0.9% saline or 3% hypertonic saline (1.5 mL/kg/hr) for 48 hr.

32 on-directed therapies (mannitol, 56% vs 21%; hypertonic saline, 14% vs 7%; hypothermia, 24% vs 10%; p

33 Clinically relevant concentrations of hypertonic saline (20 mM) significantly augmented CD69 e

34 greater increase measured using 23.4% or 30% hypertonic saline (23.4%, 365.0 +/- 8.8 mosm/L, p < .05

35 Group 2 (n = 15) received standard care and hypertonic saline (30%) via infusion to maintain serum s

36 out the 300-min period by all but the lowest hypertonic saline (4.2% NaCl).

37 e equisodium but different concentrations of hypertonic saline: 4.2%, 7.5%, 10%, 23.4%, and 30%.

38 normal saline; 2-TBI, normal saline; 3-TBI, hypertonic saline; 4-TBI, 100mM NaLac, 5-TBI, 500 mM NaL

39 y assigned to receive treatment with inhaled hypertonic saline (5 ml of 7 percent sodium chloride) fo

40 mOsm/L) as was water content of small bowel (hypertonic saline, 69.1+/-5.8%; normal saline, 74.7+/-0.

41 Hypertonic saline (7.5% NaCl) solution may maximize rena

42 Animals were treated with hypertonic saline (7.5% NaCl, 4 mL/kg) before or after c

43 Hypertonic saline (7.5%) treatment significantly attenua

44 We hypothesized that hypertonic saline (7.5%) would reverse these detrimental

45 water content was significantly reduced with hypertonic saline (73.9+/-1.1%; 359+/-10 mOsm/L) (mean+/

46 (75.6 +/- 1.3%, 339 +/- 16 mOsm/L), and 7.5% hypertonic saline (74.9 +/- 0.7%, 360 +/- 23 mOsm/L) sig

47 nitol (74.4 +/- 1.2%, 352 +/- 15 mOsm/L), 5% hypertonic saline (75.6 +/- 1.3%, 339 +/- 16 mOsm/L), an

48 .8%; normal saline, 74.7+/-0.71%) and brain (hypertonic saline, 78.1+/-0.87%; normal saline, 79.2+/-0

49 sphere of wildtype mice was attenuated after hypertonic saline (79.9% +/- 0.5%; mean +/- SEM) but not

50 ignificantly greater increase in FEV(1) than hypertonic saline (8% [2 to 14], p=0.01).

51 ine had no effect on the postischemic edema (hypertonic saline: 80.3% +/- 0.7%; 0.9% saline: 80.3% +/

52 ular action principle in mechanistic detail: Hypertonic saline acts via metalloproteinase 9 (MMP9).

53 After 60 mins, hypertonic saline administered at 50 mosm/kg resulted in

54 ined at least within high normal limits, but hypertonic saline administered to 145-155 mmol/L may be

55 The use of therapeutic interventions such as hypertonic saline administration and decompressive crani

56 Hypertonic saline administration to children with closed

57 easured over 4 h and again at 24 h following hypertonic saline administration.

58 ce remained only 50% regardless of timing of hypertonic saline administration.

59 e lung injury in wild-type mice treated with hypertonic saline after cecal ligation and puncture was

60 Osmotherapy with hypertonic saline ameliorates cerebral edema associated

61 nt isotonic and hypotonic challenges, and to hypertonic saline, an effective therapy for mucus hydrat

62 pression in the MnPN after administration of hypertonic saline and Ang-II in both spontaneously sleep

63 to compare the effects of equimolar doses of hypertonic saline and dextran solution (HSD, Rescueflow)

64 ere treated with different concentrations of hypertonic saline and endotoxin of Escherichia coli O111

65 ng advantageous resuscitative fluids such as hypertonic saline and hemoglobin-based oxygen carriers a

66 arch has demonstrated an association between hypertonic saline and hyperchloremia, limited data exist

67 ce secondary brain injury through the use of hypertonic saline and induced hypothermia.

68 Systemic administration of hypertonic saline and intracerebroventricular (i.c.v.) i

69 Hypertonic saline and mannitol are used less in infants

70 d determined the effects of osmotherapy with hypertonic saline and mannitol on total lung water, as w

71 outcome was hospital billing for parenteral hypertonic saline and mannitol use, by day of service.

72 n Brown Norway rats (N = 26) by injection of hypertonic saline and monitored for 5 weeks.

73 rmonatremic controls; concurrent infusion of hypertonic saline and myoinositol increased brain myoino

74 ormonatremic animals, concurrent infusion of hypertonic saline and myoinositol increased brain myoino

75 mber of studies show the cellular effects of hypertonic saline and no studies, to our knowledge, have

76 fibrillary acidic protein immunostaining in hypertonic saline and normal saline treated rats, and un

77 nificantly improved in patients treated with hypertonic saline and placebo, whereas the residual volu

78 active treatment group (n = 158) received 7% hypertonic saline and the control group (n = 163) receiv

79 The MnPN also contains cells responsive to hypertonic saline and to angiotensin-II (Ang-II).

80 were randomized to control (with and without hypertonic saline) and mesenteric venous hypertension wi

81 s, chronic dehydration (produced by drinking hypertonic saline) and sustained hypovolemia (produced b

82 s: 4 followed a nebulization technique using hypertonic saline, and 2 followed a chest or abdomen mas

83 3% (2,069 of 6,238) of the patients received hypertonic saline, and 40% (2,500 of 6,238) received man

84 n, 5% human albumin, 25% human albumin, 3.5% hypertonic saline, and 7.5% hypertonic saline.

85 % with hypertonic saline/dextran, 75.7% with hypertonic saline, and 75.1% with normal saline (P = .88

86 addition, vogue methods such as hypothermia, hypertonic saline, and aggressive surgical decompression

87 compared the effectiveness of daily rhDNase, hypertonic saline, and alternate-day rhDNase in children

88 The role of colloids, hypertonic saline, and hemoglobin solutions in trauma re

89 GABAergic neurones in spontaneously sleeping hypertonic saline- and Ang-II-treated rats versus respec

90 y reactivity to NK A (NKA), substance P, and hypertonic saline; and to examine HIB before and after c

91 emic encephalopathy and early treatment with hypertonic saline are critical for successful outcomes.

92 studied whether these protective effects of hypertonic saline are related to improved gammadeltaT ce

93 We used perineurial injection of hypertonic saline as a tool to open the perineurial barr

94 lung water content were attenuated with 7.5% hypertonic saline at all time points.

95 Treatment with 7.5% hypertonic saline attenuated blood-brain barrier disrupt

96 ries of experiments (n = 32), treatment with hypertonic saline attenuated postischemic blood-brain ba

97 via the perivascular pool of aquaporin-4, 2) hypertonic saline attenuates blood-brain barrier disrupt

98 ical role in water egress from brain; and 3) hypertonic saline attenuates blood-brain barrier disrupt

99 We have previously shown that treatment with hypertonic saline attenuates cerebral edema associated w

100 tested the hypothesis that osmotherapy with hypertonic saline attenuates cerebral edema following ex

101 Inhaled hypertonic saline attenuates postshock acute lung injury

102 ly higher (88%) than in animals treated with hypertonic saline before cecal ligation and puncture (50

103 of human polymorphonuclear neutrophils with hypertonic saline before stimulation with formyl methion

104 23.4% hypertonic saline bolus administration.

105 sponded linearly to intravenous infusions of hypertonic saline but with much lower slopes.

106 Blood was diluted with hypertonic saline by controlling for sodium content equa

107 he novel pharmacologic agent dexanabinol; b) hypertonic saline; c) mild hypothermia; and d) decompres

108 These data indicate that hypertonic saline can modulate gammadeltaT cell function

109 Hypertonic saline caused a decrease in CD18 cell surface

110 Hypertonic saline causes increased hydraulic conductivit

111 to 116 traits assessed through blood tests, hypertonic saline challenge tests, questionnaires, and s

112 injury was attenuated by both amiloride and hypertonic saline, combined administration of amiloride

113 ars with cystic fibrosis, the use of inhaled hypertonic saline compared with isotonic saline did not

114 At equiosmotic doses of hypertonic saline, concentration plays no substantial ro

115 nd ventricular volumes increased after 23.4% hypertonic saline, consistent with a reduction in brain

116 We investigated the hypothesis that bolus hypertonic saline decreases cerebral edema in severe hep

117 Hypertonic saline decreases intestinal edema and improve

118 Hypertonic saline, delivered by jet nebuliser, is not as

119 e hypothesis that two 4-mL x kg(-1) doses of hypertonic saline dextran (HSD; 7.5% NaCl/6% dextran-70)

120 being brought into clinical use, especially hypertonic saline dextran, haemoglobin-based oxygen carr

121 ons of patients with severe TBI (GOSE </=4) (hypertonic saline/dextran vs normal saline: 53.7% vs 51.

122 e 250-mL bolus of 7.5% saline/6% dextran 70 (hypertonic saline/dextran), 7.5% saline (hypertonic sali

123 Survival at 28 days was 74.3% with hypertonic saline/dextran, 75.7% with hypertonic saline,

124 suscitation with either hypertonic saline or hypertonic saline/dextran, compared with normal saline,

125 oinositol or infusion of myoinositol without hypertonic saline did not increase brain myoinositol lev

126 Hypertonic saline did not reduce nerve density, but did

127 5.0 +/- 8.8 mosm/L, p < .05 vs. other lesser hypertonic saline doses).

128 of intracerebral hematoma, a single dose of hypertonic saline effectively reduces the intraparenchym

129 Our findings suggest that hypertonic saline enhances the elimination of inflammato

130 had elevated IOP induced in the left eye by hypertonic saline episcleral vein injections.

131 Hypertonic saline-evoked synaptic vesicle fusion is simi

132 se data demonstrate that 1) osmotherapy with hypertonic saline exerts antiedema effects via the periv

133 We tested the hypothesis that hypertonic saline exerts its antiedema effect by promoti

134 The effect of timing of hypertonic saline exposure on A3 receptor expression and

135 ne, combined administration of amiloride and hypertonic saline failed to further protect the gut.

136 ock (shock) or traumatic brain injury (TBI), hypertonic saline failed to improve survival.

137 Hypertonic saline fluids used to resuscitate trauma pati

138 normal saline, 3% hypertonic saline, or 7.5% hypertonic saline for 24, 48, 72, and 96 hrs.

139 We hypothesized that aerosolized inhaled hypertonic saline given at the onset of resuscitation wi

140 Hypertonic saline given to children with bronchiolitis i

141 Hypertonic saline, given as intermittent boluses, has jo

142 On average, LCI decreased in the hypertonic saline group (n = 12) by 1.19 z-scores units

143 ed in an increase in serum osmolarity in all hypertonic saline groups (p < .05 vs. normal saline), wi

144 In contrast in alpha-Syn(-/-) mice, hypertonic saline had no effect on the postischemic edem

145 Hypertonic saline has been shown to be an effective osmo

146 Hypertonic saline has been shown to modulate cell shape

147 shown promise in poor grade patients, while hypertonic saline has shown better intracranial pressure

148 have shown a potential benefit of nebulized hypertonic saline; however, its effect in the emergency

149 irway dehydration could be reversed, we used hypertonic saline (HS) as an osmolyte to rehydrate ASL.

150 Pretreatment with hypertonic saline (HS) can prevent these changes.

151 urrent evidence is unclear about the role of hypertonic saline (HS) for the acute treatment of bronch

152 Two previous meta-analyses of nebulized hypertonic saline (HS) on hospital length of stay (LOS)

153 n, have found a limited benefit of nebulized hypertonic saline (HS) treatment in the pediatric emerge

154 produced by a rehydrating treatment based on hypertonic saline (HS), a current CF clinical treatment.

155 An alternative mucolytic therapy is hypertonic saline (HS); however, HS may potentiate neutr

156 efore and after intramuscular injection with hypertonic saline (HS, 5%, 100 microl).

157 Hypertonic saline (HS, i.v. bolus), which produced a phy

158 atients received 4 mL of 3% sodium chloride (hypertonic saline [HS group]) or 0.9% sodium chloride (n

159 Hypertonic saline (HTS) induces bronchoconstriction.

160 Hypertonic saline (HTS) is an accepted treatment for tra

161 ysiologic differences in neural responses to hypertonic saline (HTS) were investigated in subjects wi

162 randomized to receive either 7.2% saline/6% hypertonic saline hydroxyethyl starch (4 mL/kg) or vehic

163 y resuscitation, which was not influenced by hypertonic saline hydroxyethyl starch administration.

164 ing results in other models of brain injury, hypertonic saline hydroxyethyl starch failed to improve

165 This might explain why hypertonic saline hydroxyethyl starch has failed to impr

166 ocampal CA1 and neocortex with no effects of hypertonic saline hydroxyethyl starch on neuronal surviv

167 Hypertonic saline hydroxyethyl starch treatment resulted

168 Three percent hypertonic saline (HYS) has been suggested as a means of

169 In addition, hypertonic saline improved intestinal transit, possibly

170 Hypertonic saline improved lung function to the same deg

171 Bolus 23.4% hypertonic saline improves surveillance neuromonitoring

172 er A3 receptors may diminish the efficacy of hypertonic saline in a mouse model of acute lung injury.

173 , and show potentially beneficial effects of hypertonic saline in acute cervical SCI.

174 The Efficacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis (GUERANDE

175 to account for the effects of amiloride and hypertonic saline in CF lung disease, indicating the nee

176 a indicate the clinical benefit of nebulized hypertonic saline in cystic fibrosis lung disease, with

177 Early and continuous infusion of hypertonic saline in patients with severe cerebrovascula

178 In addition, hypertonic saline-induced Fos-ir was colocalized with th

179 e, this study focused on the hypothesis that hypertonic saline-induced improvements in histological o

180 ing a sustained experimental pain challenge (hypertonic saline infused in the masseter muscle) with a

181 50 patients with hyponatremia who underwent hypertonic saline infusion.

182 Hyper-osmolality induced via 2% hypertonic saline ingestion significantly decreased, whe

183 ratio of Mean Expiratory Flow after 240s of hypertonic saline inhalation with respect to the age- an

184 (Forced Expiratory Flow Volume after 240s of hypertonic saline inhalation; p = 4.81*10(-4)) and CD14

185 Additionally, nebulized hypertonic saline inhibited matrix -metalloproteinase-13

186 Unilateral elevation of IOP was produced by hypertonic saline injection into an episcleral vein in 2

187 ncreased saline intake after dehydration and hypertonic saline injection.

188 eurons were activated by fluid satiation and hypertonic saline injection.

189 mor outflow with laser coagulation or limbal hypertonic saline injection.

190 IOP elevation was induced in rats by hypertonic saline injections into episcleral veins.

191 IOP elevation was induced in rats by hypertonic saline injections into episcleral veins.

192 l IOP elevation was produced by injection of hypertonic saline into the episcleral veins.

193 was raised in brown Norway rats by injecting hypertonic saline into the limbal venous system.

194 was raised in Brown Norway rats by injecting hypertonic saline into the limbal venous system.

195 weeks following these injections we injected hypertonic saline intraperitoneally into the rat.

196 1.0%; contralateral, 79.7 +/- 0.6%) and 7.5% hypertonic saline (ipsilateral, 82.3 +/- 1.3%; contralat

197 Treatment with 5% hypertonic saline (ipsilateral, 83.8 +/- 1.0%; contralat

198 Hypertonic saline is an effective agent to increase seru

199 Hypertonic saline is currently being used in the treatme

200 Hypertonic saline is effective in reducing organ water c

201 Evidence for other treatments such as hypertonic saline is evolving but not clearly defined ye

202 We found that hypertonic saline is more effective than mannitol for th

203 Episcleral vein injection of hypertonic saline is more likely to increase IOP during

204 Inhaled hypertonic saline is recommended as therapy for patients

205 One of these treatments, hypertonic saline, is already in use, whereas others are

206 miloride suppresses the beneficial effect of hypertonic saline, it has been previously concluded that

207 miloride and small-volume resuscitation with hypertonic saline may be a strategy worthy of further ev

208 igible trials, but our findings suggest that hypertonic saline may be superior to the current standar

209 in water content with continuous infusion of hypertonic saline may have therapeutic implication in th

210 Through osmotic forces, hypertonic saline may increase the volume of airway surf

211 en patients with 18 administrations of 23.4% hypertonic saline met inclusion criteria.

212 Hypertonic saline mitigates intestinal edema development

213 20), 5% hypertonic saline (n = 20), or 7.5% hypertonic saline (n = 18) as a chloride/acetate mixture

214 (n = 21), 20% mannitol (2 g/Kg) (n = 20), 5% hypertonic saline (n = 20), or 7.5% hypertonic saline (n

215 uced in rats by episcleral vein injection of hypertonic saline (N = 30).

216 Although the anti-edema effects of hypertonic saline on brain are well documented in a vari

217 the effects of different tonicity of infused hypertonic saline on cerebral, lung, and small bowel wat

218 our findings and to evaluate the effects of hypertonic saline on functional outcomes.

219 We also assessed the effect of hypertonic saline on intraparenchymal pressure in differ

220 The beneficial effects of hypertonic saline on neuronal survival and on cerebral b

221 However, the effect of hypertonic saline on the macrophage remains unknown.

222 ed in a blinded randomized fashion with 7.5% hypertonic saline or 0.9% normal saline in a 8-mL/kg int

223 34), alpha-Syn(-/-) mice treated with either hypertonic saline or 0.9% saline had smaller infarct vol

224 Hypertonic saline or co-loaded cargo was found to preven

225 Treating acidic ASL with hypertonic saline or heparin largely reversed the increa

226 mic shock, initial resuscitation with either hypertonic saline or hypertonic saline/dextran, compared

227 Of the 1,854 patients who received hypertonic saline or mannitol for >/= 2 days in the firs

228 Hypertonic saline or mannitol resuscitation, therefore,

229 uous infusion only for 48 hrs of either 7.5% hypertonic saline or normal saline (1 mL/kg/hr) (n=10 ea

230 uous intravenous infusion (1 mL/kg/hr) of 5% hypertonic saline or normal saline, respectively (n=10 e

231 umin) or crystalloids (n = 1443; isotonic or hypertonic saline or Ringer lactate solution) for all fl

232 ore fluid in response to either subcutaneous hypertonic saline or water deprivation with partial rehy

233 70 (hypertonic saline/dextran), 7.5% saline (hypertonic saline), or 0.9% saline (normal saline) initi

234 us intravenous infusion of normal saline, 3% hypertonic saline, or 7.5% hypertonic saline for 24, 48,

235 Inhaled hypertonic saline osmotically draws water onto airway su

236 e interval, -1.6 to 5.7), with both favoring hypertonic saline over mannitol.

237 t concentrations of the same osmotic load of hypertonic saline over time.

238 mL vs. 3342 +/- 859 pg/mL, shock vs. shock + hypertonic saline, p = .006).

239 luid vs. 230 +/- 19 pg/mL, shock vs. shock + hypertonic saline, p = .009) and pretreatment with a mat

240 Hypertonic saline prevented intestinal tissue edema.

241 patients with cystic fibrosis, inhalation of hypertonic saline produced a sustained acceleration of m

242 Additionally, hypertonic saline reduced both neutrophil CD11b expressi

243 Nebulized hypertonic saline reduced inflammation (cytokine-induced

244 Both amiloride and hypertonic saline reduced T/HS-induced pulmonary permeab

245 th daily rhDNase, alternate-day rhDNase, and hypertonic saline, respectively.

246 syx(4) mutant animals have severely impaired hypertonic saline response in vivo, an assay indicating

247 Delayed treatment of hypertonic saline resulted in the greatest reduction in

248 S + VH + VEH) or 80 mL/kg normal saline with hypertonic saline (RESUS + VH + HTS).

249 A3 antagonists could improve the efficacy of hypertonic saline resuscitation by reducing side effects

250 l A3 receptors expression determines whether hypertonic saline resuscitation inhibits or aggravates p

251 Hypertonic saline resuscitation may therefore protect ho

252 Hypertonic saline resuscitation reduces tissue damage by

253 he effect of A3 receptors on the efficacy of hypertonic saline resuscitation was assessed in A3 recep

254 Hypertonic saline significantly lessened the effect of e

255 tion of either 1.25 g/kg ioxilan (n = 10) or hypertonic saline solution (n = 10) as a control.

256 a were induced unilaterally, by injection of hypertonic saline solution, episcleral vein cauterizatio

257 emorrhagic shock and multiple-system trauma, hypertonic saline solutions are increasingly being used

258 Randomized trials have suggested that hypertonic saline solutions may be superior to mannitol

259 n (LHSS) reward if rats are denied access to hypertonic saline solutions.

260 Highly concentrated hypertonic saline such as 23.4% provides a small volume

261 ed concentrations of menthol, capsaicin, and hypertonic saline that evoked comparable levels of nocif

262 postocclusion) was robustly attenuated with hypertonic saline therapy (ipsilateral, 81.59 +/- 0.52%;

263 cardiopulmonary resuscitation: 1) continuous hypertonic saline therapy maintained to achieve serum os

264 tischemic complication can be manipulated by hypertonic saline therapy.

265 ived unilateral episcleral vein injection of hypertonic saline to elevate IOP.

266 Interventions: Intravenous infusion of 3% hypertonic saline to increase serum sodium to levels nec

267 Intraperitoneal administration of hypertonic saline to the rat supraoptic nucleus (SON) in

268 on was not different between 0.9% saline and hypertonic saline-treated wild-type mice.

269 Effects of the timing of hypertonic saline treatment administration on tissue los

270 de values should be monitored closely during hypertonic saline treatment as moderate elevations may i

271 brain water is responsive to continuous 7.5% hypertonic saline treatment begun at 24 hrs postischemia

272 c arrest/cardiopulmonary resuscitation, 7.5% hypertonic saline treatment did not attenuate water cont

273 f water content of extracerebral organs with hypertonic saline treatment may have therapeutic implica

274 Results show that hypertonic saline treatment reduced tissue loss that cor

275 rphonuclear neutrophils are activated before hypertonic saline treatment.

276 ceptor expression and degranulation, whereas hypertonic saline-treatment after formyl methionyl-leucy

277 This aggravating effect of delayed hypertonic saline-treatment was absent in A3 receptor kn

278 ly, mortality in wild-type mice with delayed hypertonic saline-treatment was significantly higher (88

279 comes Consortium multicenter out-of-hospital Hypertonic Saline Trial in patients with Glasgow Coma Sc

280 Hypertonic saline triggers polymorphonuclear neutrophils

281 ating that there is a therapeutic window for hypertonic saline use after traumatic brain injury.

282 Hypertonic saline use increased and mannitol use decreas

283 %; difference, 2.2% [95% CI, -4.5% to 9.0%]; hypertonic saline vs normal saline: 54.3% vs 51.5%; diff

284 urther increased to 31.8 +/- 3.1% when 20 mM hypertonic saline was added with lipopolysaccharide.

285 In the study group, nebulized hypertonic saline was delivered at the end of the shock

286 The efficacy of hypertonic saline was equivalent to furosemide (ipsilate

287 Hypertonic saline was injected into a single episcleral

288 Hypertonic saline was instituted as chloride/acetate mix

289 to 1510) and that between daily rhDNase and hypertonic saline was pound1409 (440 to 2318).

290 A single episcleral vein injection of hypertonic saline was used to sclerose aqueous humor out

291 Volumes before and after 23.4% hypertonic saline were compared with Wilcoxon signed ran

292 this study, we tested the hypothesis that a) hypertonic saline when given as an intravenous bolus and

293 , and brain water content is attenuated with hypertonic saline when serum osmolality is >350 mOsm/L w

294 amage was induced by episcleral injection of hypertonic saline, which caused sclerosis and blockade o

295 ence interval, 1.6 to 11.7; P=0.02), whereas hypertonic saline with amiloride did not improve FEV1 (m

296 mal rats respond to intravenous infusions of hypertonic saline with gradual, linear increases in disc

297 Furthermore, inhalation of hypertonic saline with placebo improved the forced expir

298 ing treatment with continuous IV infusion 3% hypertonic saline, with moderate hyperchloremia independ

299 onatremic and hyponatremic rats, infusion of hypertonic saline without myoinositol or infusion of myo

300 Long-term inhalation of hypertonic saline without pretreatment with amiloride (i